Abstract Acute promyelocytic leukemia (APL) typically demonstrates the translocation t(15;17)(q24;q21) leading to PML-RARA fusion in~92 % of the cases. The remaining t (15;17) negative APL-like cases may have other cytogenomic rearrangements, including cryptic PML-RARA fusion, translocation variants, or MYC gene amplification. The morphologic and cytogenetic profile of the APL-like cases with MYC amplification and the prognostic implications are largely unknown due to rarity of these cases. Here, we present a case of acute myeloid leukemia with promyelocytic morphology lacking the classic t(15;17) and RARA rearrangement, with der(5)t(5;17)(q13;21), MYC deletion, double minutes, and two cell lines with amplification of the MYC region. The two cell lines differed in contribution to the proportion of the cells and copy number of the amplified probes during the clinical course. This is likely the first case with such a complex molecular cytogenetic evolution detailed in the same patient. Literature review revealed that most of the APL-like cases with MYC amplification have no t(15;17) and PML-RARA (78.5 %; 7/8 cases) but a complex karyotype (75 %; 6/8 cases). Deletion 17p/monosomy 17 and deletion 9p/monosomy 9 are reported in~40-50 % of the cases and are associated with poor prognosis. MYC amplification alone may not be a reliable prognostic indicator in APL-like cases. Our findings can be very helpful for clinicopathologic/cytogenetic correlation and potentially management of such rare but potentially unrecognized APL-like patients.
Introduction
Acute promyelocytic leukemia (APL) is characterized by a proliferation of blasts and morphologically abnormal promyelocytes in the bone marrow and peripheral blood. Diagnosis of APL requires demonstration of rearrangements involving RARA (17q21). A vast majority (~92 %) of APL cases have the classic translocation t(15;17)(q24;q21) leading to PML-RARA fusion [1] . The remaining t(15;17) negative APL cases may have (1) cryptic insertions or other rearrangements leading to PML-RARA fusion detectable by FISH, RT-PCR, long-distance DNA-PCR or sequencing analysis; and (2) translocation variants [1] [2] [3] . Seven translocation variants have been reported with a fusion of RARA to one of the partner genes: PLZF (or ZBTB16) at 11q23, NUMA1 at 11q13, NPM1 at 5q35, STAT5B at 17q21, PRKAR1A at 17q24, FIP1L1 at 4q12, and BCOR at Xp11 [1, 3] . Patients with PML-RARA, NPM1-RARA, and NUMA1-RARA respond to treatment with all-trans retinoic acid (ATRA), while those with PLZF-RARA and STAT5B-RARA do not [1, 3, 4] . Other common aberrations in APL include trisomy 8, deletion 9q, and ider(17)(q10)t(15;17) [5] .
Amplification of MYC (8q24) is reported in rare cases of cancer; more often in solid tumors than leukemias. MYC amplification can be seen as double minutes (dmin) (e.g., double dots, larger spherical or fragment structures and rings) or homogeneously stained regions [6] [7] [8] . Gene amplification in cancers can confer growth advantage to the mutated cells and is often associated with disease progression, drug resistance, and poor prognosis. MYC amplification has been reported in seven APL-like cases, and its prognostic significance is not well understood [7] [8] [9] [10] [11] [12] [13] .
Here, we present a case of acute myeloid leukemia (AML) with promyelocytic morphology lacking the classic t (15;17) and RARA rearrangement and with der(5)t (5;17)(q13;21), MYC deletion, dmin, and two cell lines with amplification of the MYC region.
Case report
A 62-year-old woman presented with a recent history of community-acquired pneumonia treated with antibiotics; after which, persistent fatigue and dysgeusia was noted. A complete blood count showed leukocytosis with blasts and promyelocytes in the peripheral blood. On admission, she did not have any active bleeding, and her physical exam was unremarkable. Initial laboratory assessment showed a white blood cell count of 32.3 × 10 9 /L (normal 4-10) with elevated blasts at 9.7 × 10 9 /L (30 % of total leukocytes). Her hemoglobin was 79 g/L (normal 115-160) with a platelet count of 47 × 10 9 /L (normal 150-400). Her INR was 1.0 (normal 0.9-1.1), with a PTT of 29 s (normal 25-37) and a fibrinogen of 4.04 g/L (normal 2-4). Her serum LDH level was markedly elevated at 1,995 u/L (normal ≤214) with a urate level of 442 mol/L (normal ≤340), a phosphate level of 1.98 mol/L (normal 0.80-1.33), and creatinine of 89 mol/L (normal 55-100). A bone marrow aspirate showed heavy infiltration by a combination of myeloblasts (approximately 30 % of all nucleated cells) and hypergranular promyelocytes (approximately 50 % of all nucleated cells) (Fig. 1) . Auer rods were identified but not prominent. Flow cytometric analysis of the bone marrow identified a myeloblast/promyelocyte population representing 80 % of the total nucleated cells; expressing CD33 and CD15; partial expression of CD117, CD11b, CD13, and HLA-DR; dim expression of CD10; and negative expression of CD56, CD16, MY4, and CD34. The morphological and immunophenotypical findings were consistent with AML with promyelocytic morphology. The patient underwent standard induction chemotherapy with 3 + 7 (cytarabine (100 mg/m 2 ) and daunorubicin (180 mg/m 2 )). After G-banding identification of absence of the classic t(15;17), but with the translocation t (5;17) (see Molecular cytogenetics results), the patient was started on ATRA 45 mg/m 2 which she tolerated well until time of discharge. The decision of using ATRA was based on previous reports that APL patients bearing the t(5;17) translocation might respond to this drug [14] . On achieving morphological remission and improvement in cytogenetic findings, a decision was made to continue with two consolidations with daunorubicin (150 mg/m 2 ) plus ATRA. Subsequently, she was started on maintenance chemotherapy with 6-MP, Methotrexate, and ATRA. A subsequent bone marrow aspirate on day 125 showed cytogenetic evolution (see below for details of cytogenetics) and morphological relapse (82 % of total leukocytes were myeloblasts/promyelocytes). She was readmitted to the hospital with morphological relapse for reinduction with FLAG (Fludarabine 30 mg/m 2 days 1-5, Cytarabine 2 g/m 2 days 1-5, and Filgrastim until neutrophil recovery) without achieving remission. She was then started on arsenic trioxide (0.15 mg/kg/day) on day 157 but developed a complete heart block and acute renal failure 6 days later, and a decision was made to withdraw care. She died 180 days after diagnosis.
Molecular cytogenetics results

Diagnosis
Interphase FISH analysis of 200 cells was performed on the bone marrow aspirate using PML-RARA dual color and dual fusion translocation probes (Abbott Molecular, Abbott Park, Illinois), which demonstrated no abnormality. The lack of RARA rearrangement (break apart or fusion) was confirmed by FISH using the RARA break apart and dual color probe (Abbott Molecular).
G-banding analysis showed a complex karyotype characterized by the absence of the classic t(15;17) but with der(5)t (5;17)(q13;q21), monosomy 17, deletion 9q22, and 14-100 dmin (Table 1 and Fig. 2a, f) . To further delineate the der(5), metaphase FISH was done using a Miller-Dieker/Lissencephaly (LIS1) region probe set with a SpectrumOrange probe for the LIS1 (17p13.3) and SpectrumGreen probe for RARA (17q21) (Abbott Molecular). It should be pointed out that while the short arm of the der(5) was slightly larger than that of chromosome 17, the two chromosomes could not be readily distinguished from each other due to similar overall length and G-banding pattern, especially in the cells with short chromosomes and suboptimal banding quality (Fig. 2f ). The LIS1(17p13.3) was used to help differentiate der(5) from chromosome 17. Figure 2f (middle) showed intact orange LIS1 and green RARA signals on chromosome 17 but only the green RARA in der(5). This confirmed translocation of the 17q segment containing RARA to the der(5) with the breakpoint being proximal to RARA. Furthermore, FISH using RARA break apart and dual color probes showed normal pattern in interphase cells and the presence of an intact RARA signal in both der(5) and chromosome 17 in metaphase cells and no evidence of RARA break apart or fusion ( Fig. 2f; lower). The metaphase FISH results explain the presence of two intact RARA signals in all interphase cells despite monosomy 17 detected in all G-banded metaphase cells.
To characterize the dmin, FISH was performed using a MYC (8q24) break apart and dual color probe set (Cytocell; LPH010; Rainbow Scientific Inc., Windsor). The Cytocell product consists of two probes spaced 712,133 bp apart. The proximal red probe (173 Kb; chr 8: 128248316-128421245) is located 332 Kb 3′ of the MYC gene, while the distal green probe (186 Kb; chr8: 129133378-129319742) is 380 Kb 5' of the gene. The FISH showed that 41 % of the 200 cells had 30-50 red/green fusion signals, indicative of amplification of the whole probe, while 59 % of the cells had 30-50 red signals, indicative of amplification of 3′of the probe (Fig. 2d) . Notably, all interphase and metaphase cells with amplification of red 3′ of the probe had only one red/green fusion signal (arrow in Fig. 2b-d) , indicative of a deletion of the MYC. The MYC deletion was confirmed by FISH using a 3-color probe set with MYC(8q24)/orange, CEP8/aqua, and IGH(14q32)/green (Fig. 2e) .
Evaluation during clinical course
Four cytogenetic and FISH evaluations were performed on day 30, 90, 125, and 157 during the 6-month clinical course. The evaluations showed dynamic changes in (1) types of chromosome aberrations and (2) the proportion of the two cell lines with the amplification (Table 1) . G-banding analysis of unstimulated blood on day 30 showed the same types of abnormalities as seen at diagnosis, but the proportion of abnormal cells decreased to 24 % (6/ 25) from the previous 100 % (25/25). Of the six abnormal cells, five (20 %) cells had~8-50 dmin, a decrease from the previous~14-100 dmin. Similarly, cells with FISH amplification of red 3′ of the probe decreased to 8 % from 59 %, and cells with FISH amplification of the whole probe decreased to 3.5 % from 41 %. Of note, copy number of the amplified whole probe decreased to 9-11 from the previous 30-50.
The last three evaluations showed continuing cytogenetic evolution with additional aberrations emerging with each subsequent test: deletion 13q, monosomy 14, and an extra marker on day 90; loss of X, additions in 11q23, 17p11.2, and 19q13.4, and duplication of 15q11.2q15 on day 125; and deletion 1q, monosomy 7, trisomy 21, and a second marker on day 157. The incidence of abnormal cells by Gbanding was 48 % (12/25) on day 90 and then increased to 100 % (25/25) on day 125 and (8/8) on day 157. FISH amplification of the whole MYC probe was seen in 0.5 % of the cells on day 90 and~3 % on days 125 and 157, while amplification of 3′ of the probe was seen in 14.5 % of the MYC amplification (red) on dmin, (2) a normal chromosome 8 (red arrow) with intact cen8 (aqua) and MYC (red) signals, and( 3) a deleted chromosome 8 (white arrow) with cen8 (aqua) but loss of MYC signal. f upper: G-banded chromosomes 5, der(5)t(5;17)(q13; q21) and 17; middle: FISH using LSI LIS1 (17p13.3, SpectrumOrange) and RARA (17q21.1; SpectrumGreen) and showing a normal 17 with both orange and green probes and der(5) with RARA and confirming translocation of RARA to der(5) and the breakpoint being proximal to RARA; lower: FISH using break apart and dual color (red/green) probe and showing an intact probe in both der(5) and chromosome 17 and no evidence of break apart or fusion of RARA cells on day 90 and then increased to >80 % on days 125 and 157.
Discussion
To the best of our knowledge, the present case is the second reported APL-like case without PML-RARA fusion but with a der(5)t(5;17)(q13;21) as part of a complex karyotype and MYC amplification and deletion. A previous APL case with der(5)t(5;17)(q13;21), del(8)(q22q24), der(17), 5-32 dmin was RT-PCR negative for PML-RARA, PLZF-RARA, NPM-RARA, NuMA-RARA, and STAT5b-RARA [10, 15] . The presence of der(5)t(5;17) at diagnosis and/or relapse in the previous cases and that of our results suggests that the der(5) is a primary aberration. More case reports and molecular cytogenetic studies would help address the question of whether or not the der(5) with a reunion of the cytogenetic segments 5q13::17q21 generates a gene fusion product/protein and/or plays a role in tumorigenicity.
MYC amplification has been reported in at least eight AML cases with promyelocytic differentiation, including the present case ( Table 2) . Four of the six cases tested by FISH had MYC deletion [7, 10, 13 , and present case], and one case had monosomy 8 by G-banding [9] . Interestingly, trisomy 8, the most common finding in AML, is absent in all of the eight cases. A majority of the eight cases demonstrated amplification as well as deletion of MYC. This suggests a significant role of MYC deletion in MYC amplification in these APL-like cases and supports the hypothesis of a sequence of deletion, replication, looping, and then amplification of the MYC region [18] . Our FISH showed that the amplification signals were on dmin and distributed more or less evenly throughout the interphase and metaphase cells in both cell lines (see Fig. 2 ). This is different from the previous findings by Frater et al. [7] and Bruyere et al. [8] in that dmin were often seen at periphery of the nuclei or assembled together in metaphase cells and appeared to be eliminated or expelled from some cells in the form of a MYC-positive micronuclei or ball. The elimination and exclusion of the MYC-amplified genetic material might occur before or during treatment in the patient [7] or in vitro experiment with HL-60 cell line [17] and might be one of possible mechanisms for cytogenetic response [7] . It is difficult to assess clinical significance of MYC amplification in these APL-like cases because of variations in patient history, clinicopathologic presentations, cytogenetic findings, and treatment. Nevertheless, review of the eight APL-like cases with MYC amplification showed that two cases had unfavorable results; one patient died of CNS involvement 6 weeks after diagnosis [9] and another died of infection on day 14 [10] . In two other cases, one with t (15;17) and PML-RARA fusion [13] and another without [7] , had a rapid response to induction. These findings suggest that MYC amplification alone may not be a reliable prognostic indicator in the APL-like cases although it has been linked to poor prognosis in some cases of MDS and AML (most commonly M2) [16, 18] . Notably, the classic t(15;17) and/or PML-RARA fusion, a diagnostic hallmark in APL, is absent in seven (78.5 %) of the eight APL-like cases with MYC amplification (see Table 2 ). There appears to be some degree of "mutual exclusion" between MYC amplification and t(15;17) and/or PML-RARA fusion in these cases. Since PML-RARA fusion is the target for ATRA treatment, lack of the PML-RARA in these patients may be one of the reasons why most patients demonstrated a lack of response with conventional treatment.
It is well known that complex cytogenetic abnormalities are also associated with adverse prognosis in patients with acute leukemia. Six of the eight cases with MYC amplification had a complex karyotype ( Table 2 ). The eight cases implicated a total of 22 chromosome aberrations as identified by G-banding. Deletion 17p and/or monosomy 17 were seen in four cases; deletion 9p and/or monosomy 9 in three cases; and der(5)t(5;17)(q13;q21) in two cases. Notably, three patients with the chromosome 9 aberrations died between 6 weeks and 8 months after diagnosis [8, 9, 12] . Two patients without the chromosome 9 aberrations and deletion17p/monosomy 7 had a rapid response to induction. These findings suggest that deletion 9p/monosomy 9 and deletion 17p/monosomy 17 are often associated with APLlike cases having MYC amplification [8] and poor prognosis.
In conclusion, acute leukemia cases with similar morphology to APL and non-diagnostic chromosomal rearrangements (e.g., der(5)t(5;17), deletions of chromosomes 9 and 17, and dmin) and lacking the classic t(15;17) do occur. It is unclear if an APL-treatment strategy (e.g., therapy including ATRA or AsO3) should be implemented for those cases, but prognosis appears to be poor irrespective of therapies used.
